10-Q: Inogen Reports Q2 2026 Results: Revenue Up, Net Loss Widens

Inogen, Inc. announced its second quarter 2026 financial results, showing a 3.0% increase in total revenue to $95.1 million, but a widening net loss of $3.9 million.

Summary

• Total revenue for the three months ended June 30, 2026, increased by 3.0% to $95.1 million compared to $92.3 million in the same period last year.
• Sales revenue grew by 5.5% to $83.5 million, driven by international demand and favorable foreign exchange rates, with portable unit sales up 12.0%.
• Rental revenue decreased by 11.8% to $11.6 million due to fewer patients on service.
• Net loss for the quarter was $3.9 million, an increase from $4.2 million in the prior year's quarter.
• Research and development expenses increased by 12.7% to $5.9 million.
• Sales and marketing expenses decreased by 2.2% to $24.8 million.
• General and administrative expenses increased by 4.8% to $17.7 million, partly due to stockholder engagement costs.
• The company had $87.3 million in cash and cash equivalents and $18.3 million in marketable securities as of June 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to slightly negative quarter, with revenue growth offset by increased net loss and a decline in rental revenue. While sales are up, the overall profitability picture is concerning.

Positives

• Total revenue increased by 3.0% to $95.1 million for the quarter.
• Sales revenue saw a 5.5% increase, reaching $83.5 million, driven by international markets and favorable foreign exchange rates.
• Portable unit sales increased by 12.0% to approximately 53,300 units.
• Gross margin on sales revenue improved to 46.2% from 45.1% due to manufacturing cost leverage and lower component costs.
• The company's cash and cash equivalents stood at $87.3 million, with marketable securities at $18.3 million, indicating a solid liquidity position.

Negatives

• Net loss for the quarter was $3.9 million, a slight increase from $4.2 million in the prior year's quarter.
• Rental revenue decreased by 11.8% to $11.6 million due to fewer patients on service.
• Research and development expenses increased by 12.7% to $5.9 million.
• General and administrative expenses increased by 4.8% to $17.7 million, including higher stockholder engagement and proxy defense costs.
• Net loss for the six months ended June 30, 2026, increased by 17.9% to $12.2 million.

Risks

• Potential for future supply chain constraints and increases in cost and limited availability of raw materials and components.
• Inflationary pressures, interest rates, global conflicts, and monetary policy changes could negatively impact business operations.
• Changes in reimbursement rates, competitive bidding, and CMS decisions for home oxygen could affect rental revenue.
• Competitors may introduce lower-priced or more feature-rich products.
• The company's ability to attract and retain key talent is crucial.
• Geopolitical dynamics may create economic, supply chain, and energy challenges.
• International conflicts can increase transportation and freight expenses and restrict international trade.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities, along with expected cash from product sales and rentals, will be sufficient to meet projected operating and investing requirements for at least the next 12 months. They may seek additional funds through equity or debt financings if needed.

Management Comments

• The increase in sales revenue was primarily attributable to higher demand in our international markets as well as the favorable impact of foreign exchange rates, partially offset by channel mix within the U.S.
• The decrease in rental revenue was primarily related to fewer patients on service.
• Gross margin on sales revenue increased due to manufacturing cost leverage from higher units sold and lower cost premiums associated with open-market purchases of semiconductor chips and reduced warranty-related costs.
• Gross margin on rental revenue decreased primarily due to higher logistics costs per rental patient.

Industry Context

StockSavvy.ai notes that Inogen operates in the competitive respiratory care market. The reported revenue growth, particularly in international sales, aligns with broader trends of increasing demand for home-based respiratory solutions. However, the decline in rental revenue and the widening net loss highlight ongoing challenges related to patient acquisition and operational efficiency within the sector.

Legal Proceedings

• The company is party to various legal proceedings and investigations arising in the normal course of business.
• The company does not anticipate that any of these proceedings will have a material adverse effect on its business.
• Litigation can have an adverse impact due to defense and settlement costs and diversion of management resources.

Stakeholder Impact

• Shareholders may be concerned by the widening net loss and the decline in rental revenue, despite overall revenue growth.
• Employees may be impacted by increased R&D and G&A expenses, though sales and marketing expenses saw a slight decrease.
• Customers may benefit from continued product development and potential international market expansion.
• Suppliers may be affected by the company's ongoing monitoring of tariffs and supply chain challenges.

Next Steps

• Continue to expand domestic and international business-to-business channels.
• Improve productivity of direct-to-consumer and prescriber sales efforts.
• Optimize rental revenue through targeted prescriber engagement.
• Invest in research and development and clinical studies for product innovation.
• Leverage partnerships, such as with Yuwell, to broaden product portfolio and enter new markets.
• Develop and commercialize new products and expand existing offerings, including Simeox and CPAP mask lines.
• Pursue geographic expansion, particularly in Europe and other international markets.
• Monitor tariffs and trade regulations and their potential impact on the supply chain.

Key Dates

Recommendation

The company shows revenue growth, particularly in international sales, and improved gross margins on sales. However, the widening net loss, declining rental revenue, and increased operating expenses present significant concerns. The solid cash position provides some buffer, but the overall trend suggests a cautious 'hold' approach until profitability improves and rental revenue stabilizes.

Keywords

oxygen concentrator, respiratory products, medical technology, home medical equipment, sales revenue, rental revenue, net loss, cash flow